TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF
申请人:The Broad Institute, Inc.
公开号:US20200109154A1
公开(公告)日:2020-04-09
The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
本公开提供了Formula (I)的化合物,以及其盐、溶剂合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记衍生物和前药。所提供的化合物可能对抑制激酶,例如糖原合成酶激酶3(GSK3)具有用处。所提供的化合物可能能够选择性地抑制GSK3a,相对于GSK3P和/或其他激酶。本公开还提供了涉及这些化合物的药物组合物、试剂盒和使用方法。这些化合物、药物组合物和试剂盒可能对治疗与GSK3a异常活性相关的疾病有用(例如脆性X综合征、注意缺陷多动障碍(ADHD)、儿童癫痫、智力障碍、糖尿病、急性髓性白血病(AML)、自闭症和精神障碍)。